• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int Forum Allergy Rhinol . Pro-inflammatory markers associated with COVID-19-related persistent olfactory dysfunction

tetano

Editor, Senior Moderator
Int Forum Allergy Rhinol


. 2023 Sep 7.
doi: 10.1002/alr.23264. Online ahead of print. Pro-inflammatory markers associated with COVID-19-related persistent olfactory dysfunction

Sophie S Jang[SUP] 1 [/SUP], Kwang S Pak[SUP] 1 [/SUP], Allyssa Strom[SUP] 2 [/SUP], Leslie Gomez[SUP] 1 [/SUP], Laura Kim[SUP] 1 [/SUP], Taylor A Doherty[SUP] 2 [/SUP], Adam S DeConde[SUP] 1 [/SUP], Allen F Ryan[SUP] 1 [/SUP], Carol H Yan[SUP] 1 [/SUP]



Affiliations
Abstract

Introduction: While localized inflammation has been implicated in the pathophysiology of acute coronavirus disease of 2019 (COVID-19) olfactory dysfunction (OD), persistent COVID-19 OD remains poorly understood with limited therapeutics. Our prospective study evaluated olfactory cleft (OC) biomarkers as predictors of persistent OD in mucus sampling.
Methods: COVID-19 subjects with persistent OD >3 months confirmed by psychophysical olfaction tests were compared to COVID-19 subjects with no OD and those with no prior infection. OC mucus samples were evaluated for 13 anti-viral and inflammatory biomarkers. Cohorts were compared using analysis of variance (ANOVA) and Mann-Whitney tests with multi-comparison adjustment. Viral RNA was assessed through RT-PCR using the COVID-19 N2 primer.
Results: Thirty-five samples were collected (20 COVID persistent OD, 8 COVID no OD, and 7 non-COVID no OD). Significant differences in IFN-λ1 (p = 0.007) and IFN-γ (p = 0.006) expression in OC mucus were found across all three groups, with the highest cytokine concentrations corresponding to COVID OD. IFN-α2 levels were elevated in COVID OD versus no OD (p = 0.026). Mean IFN-γ levels were the highest in COVID OD, but there were higher levels found in COVID no OD compared to non-COVID no OD (p = 0.008). No difference was seen in IL6. No N2 gene expression was detected in all cohorts.
Conclusion: IFN pathway cytokines were found elevated in the olfactory microenvironment of COVID-19 persistent OD compared to those with no OD and no prior history of COVID-19 infection.

Keywords: COVID-19; long haulers; mucus; olfactory dysfunction; persistent smell loss; pro-inflammatory.

 
Back
Top Bottom